Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation

Chengyue Wang1,2, Chengyuan Yu1,3, Haijiao Jing1

  • 1Department of Hematology, The First Hospital of Harbin, Harbin Medical University, Harbin, China.

Insights

Long COVID, a thrombotic sequela, causes lasting health issues due to persistent inflammation and vascular damage. Early anticoagulation therapy shows promise in preventing complications and improving patient quality of life.

Area of Science:

  • Medical Research
  • Pathophysiology
  • Thrombosis

Background:

  • Long COVID sequelae reduce quality of life and increase healthcare burdens.
  • Pathophysiological mechanisms include persistent viral replication, hypoxia, inflammation, and vascular endothelial damage.
  • Thrombosis and vasculitis contribute to organ dysfunction and disease progression.

Purpose of the Study:

  • To summarize evidence on coagulation abnormalities in long COVID.
  • To focus on the pathophysiological mechanisms of thrombosis in long COVID.
  • To review research on antithrombotic therapy for COVID-19 and long COVID.

Main Methods:

  • Literature review of evidence for coagulation abnormalities in long COVID.
  • Analysis of pathophysiological mechanisms, including the role of extracellular vesicles (EVs).
  • Summary of recent research on antithrombotic therapy in COVID-19 and long COVID.

Main Results:

  • Long COVID is characterized by persistent systemic vascular inflammation and dysfunction driven by thrombosis.
  • Extracellular vesicles (EVs) contribute to thrombosis by carrying SARS-CoV-2 and expressing procoagulant factors.
  • Pulmonary complications like hypertension, embolism, and fibrosis are common, exacerbating hypoxia and coagulation abnormalities.

Conclusions:

  • Long COVID is fundamentally a thrombotic sequela with no current effective treatments.
  • Early prophylactic anticoagulation may prevent thrombotic sequelae, protect vascular endothelium, and improve patient outcomes.
  • Antithrombotic therapy offers a potential strategy to mitigate long COVID complications and enhance quality of life.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
37
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
50
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
949
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
49
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
59